๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lanzhou
Clinical trial register · China

Clinical Trials in Lanzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.30 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.10 LanZhou University8 Sun Yat-sen University8 Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.7
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Lanzhou

261 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Not yet open
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Active, closed
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287Primary IgA Nephropathy
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
NCT05590871Hypertension
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Recruiting
Post-market European & Asian Registry to Evaluate the Minosโ„ข Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech๏ผˆGroup๏ผ‰Co., Ltd
Observational
200
Lanzhou, Meizhou, Shenzhen, Changsha, Xiangtan, Yueyang, Zibo, Binhai
2023-03-05
Active, closed
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
NCT05751967Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Active, closed
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087Mantle Cell Lymphoma (MCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naรฏve Participants With Acute Myeloid Leukemia
NCT05736965AML, Adult
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Chโ€™ang-chโ€™un, Haโ€™erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Not yet open
Displacement of Iodine Balance Value During Pregnancy and the Mechanism of Breast Iodine Homeostasis During Lactation
NCT05730803Nutritional Requirements
Tianjin Medical University
Observational
1,200
Lanzhou, รœrรผmqi
2023-02-17
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
BeiGene
Phase 1/2
113
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2023-01-09
Recruiting
Registry Study for Optimal Management of Liver Failure in the Chinese Population
NCT05740696Liver Failure
First Affiliated Hospital Xi'an Jiaotong University
Observational
500
Xi'an, Ankang, Changsha, Hanzhong, Jinan, Lanzhou, Weinan, Xianyang
2023-01-06
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Recruiting
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128Respiratory Infectious Diseases
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Active, closed
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
NCT05511792Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-06-27
Recruiting
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Longyan, Ningde, Putian, Sanming, Zhangzhou, Lanzhou, Shenzhen
2022-06-01
Recruiting
A Prognostic Model for Drug-induced Liver Injury in China
NCT05060289Drug-induced Liver Injury
Beijing Friendship Hospital
Observational
3,000
Beijing, Dalian, Guangxi, Hebei, Jiaozuo, Lanzhou, Qingdao, Qinghai
2022-05-25
Active, closed
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
NCT05352074Slow Transit Constipation, Surgery
Third Military Medical University
Not applicable
252
Yuzhong, Lanzhou, Wuhan, Nanjing, Shengyang, Qingdao, Pudong, Xiโ€™an
2022-03-27
Active, closed
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
NCT05285826Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691HER2-positive Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Recruiting
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
NCT05498974Type1diabetes, Diabetes
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Active, closed
Long-term Efficacy and Safety Study of GV-971
NCT05181475Alzheimer Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Not yet open
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasโ„ข BRS System
NCT04995159Coronary Heart Disease
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
Newly Diagnosed Glioblastoma
NCT04959500Glioblastoma
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Recruiting
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT04987086Renal Cancer, Metastases, PSMA PET
Xijing Hospital
Not applicable
300
Lanzhou, Yinchuan, Xining, Xi'an, Weinan, Xianyang, Yanโ€™an
2021-06-01
Recruiting
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
Harbin Medical University
Not applicable
250
Hefei, Lanzhou, Harbin, Mudanjiang, Zhengzhou, Wuhan, Xi'an, Taiyuan
2021-05-27
Active, closed
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Recruiting
Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer
NCT04527861Colorectal Cancer, Colon Cancer, Rectal Cancer
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Recruiting
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
NCT07492927Clinically Significant Prostate Cancer
Xijing Hospital
Observational
1,700
Lanzhou, Yinchuan, Xining, Weinan, Xi'an, Xianyang, Yanโ€™an
2021-03-12
By invitation
Plasma Exosome RNA to Diagnose Prostate Cancer
NCT06604130Prostate Cancer
Xijing Hospital
Not applicable
1,600
Lanzhou, Yinchuan, Xining, Weinan, Xi'an, Xianyang, Yanโ€™an
2021-03-12
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
238
Beijing, Xicheng District, Lanzhou, Guangzhou, Haikou, Zhengzhou, Changsha, Xuzhou
2021-03-09
Recruiting
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
NCT07553780High-risk Prostate Cancer, PSMA PET, Treatment Response, Therapy Monitoring
Xijing Hospital
Observational
110
Lanzhou, Yinchuan, Xining, Weinan, Xi'an, Xianyang, Yanโ€™an
2021-03-07
Recruiting
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naรฏve Men With Suspected Prostate Cancer
NCT07531329Treatment-naive Prostate Cancer, Suspected Prostate Cancer, Molecular Imaging
Xijing Hospital
Observational
1,000
Lanzhou, Yinchuan, Xining, Weinan, Xi'an, Xianyang, Yanโ€™an
2021-03-05
Active, closed
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT04765657Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
NCT04523272Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
528
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan
2020-08-25
Recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
NCT06524427Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04344158Advanced Hepatocellular Carcinoma (HCC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
648
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2020-08-11
Active, closed
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143CKD (Chronic Kidney Disease) Stage 5D
Guangdong Provincial People's Hospital
Phase 4
9,082
Fuzhou, Longyan, Lanzhou, Dongguan, Foshan, Guangzhou, Guanzhou, Heyuan
2020-07-30
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337Medullary Thyroid Cancer
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Recruiting
Multicenter Cohort Study on Osteoporosis
NCT02958020Osteoporosis
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Rows per page Showing 201–261 of 261
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/lanzhou?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 261 of those studies with a site in Lanzhou.

How many clinical trials are recruiting in Lanzhou?

147 of the 261 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 50 have not yet opened recruitment, 57 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.